Drug resistance interpretation: PR

HIVDB 9.5.1 (2023-11-05)

PI Major Mutations: None
PI Accessory Mutations: None
PR Other Mutations: L10V 99% (n=2,269) • T12A 100% (n=2,302) • I13V 99% (n=2,302) • I15V 99% (n=2,929) • E35D 99% (n=2,632) • M36I 100% (n=2,635) • R41K 96% (n=2,177) • R57K 99% (n=2,308) • D60E 100% (n=2,303) • H69K 99% (n=2,284) • L89M 100% (n=2,328)

Protease Inhibitors	
atazanavir/r (ATV/r)	Susceptible
darunavir/r (DRV/r)	Susceptible
fosamprenavir/r (FPV/r)	Susceptible
indinavir/r (IDV/r)	Susceptible
lopinavir/r (LPV/r)	Susceptible
nelfinavir (NFV)	Susceptible
saquinavir/r (SQV/r)	Susceptible
tipranavir/r (TPV/r)	Susceptible

PR comments

Other

- **L10I/V** are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations.

Mutation scoring: PR

HIVDB 9.5.1 (2023-11-05)

No drug resistance mutations were found for PI.

Drug resistance interpretation: RT

HIVDB 9.5.1 (2023-11-05)

NRTI Mutations: None
NNRTI Mutations: None
RT Other Mutations: K11T 100% (n=2,406) • K20R 100% (n=2,403) • V21I 100% (n=2,407) • V35T 100% (n=2,227) • T39K 100% (n=2,412) • E53D 100% (n=2,214) • V60I 100% (n=2,533) • K103R 100% (n=2,139) • K122E 100% (n=2,370) • D123S 99% (n=2,368) • A158S 100% (n=2,356) • S162A 100% (n=2,196) • K173R 99% (n=2,356) • Q174K 100% (n=2,356) • D177E 100% (n=2,359) • E194G 100% (n=2,852) • I195L 100% (n=2,832) • G196E 99% (n=2,832) • T200A 100% (n=2,822) • I202V 100% (n=2,826) • Q207A 100% (n=2,221) • R211K 100% (n=2,234) • V245Q 100% (n=2,280) • E248D 100% (n=2,256) • V559I 100% (n=17

Nucleoside Reverse Transcriptase Inhibitors	
abacavir (ABC)	Susceptible
zidovudine (AZT)	Susceptible
stavudine (D4T)	Susceptible
didanosine (DDI)	Susceptible
emtricitabine (FTC)	Susceptible
lamivudine (3TC)	Susceptible
tenofovir (TDF)	Susceptible

Non-nucleoside Reverse Transcriptase Inhibitors	
doravirine (DOR)	Susceptible
efavirenz (EFV)	Susceptible
etravirine (ETR)	Susceptible
nevirapine (NVP)	Susceptible
rilpivirine (RPV)	Susceptible

RT comments

Other

- **K103R** is a polymorphic mutation that alone has no effect on NNRTI susceptibility. However, in combination with V179D, it reduces NVP and EFV susceptibility about 15-fold.

Mutation scoring: RT

HIVDB 9.5.1 (2023-11-05)

No drug resistance mutations were found for NRTI.

No drug resistance mutations were found for NNRTI.

Drug resistance interpretation: IN

HIVDB 9.5.1 (2023-11-05)

INSTI Major Mutations: None
INSTI Accessory Mutations: None
IN Other Mutations: V31I 98% (n=114) • I60M 100% (n=84) • V201I 99% (n=92) • I208M 99% (n=88) • K219N 100% (n=92) • N222K 100% (n=92) • S255N 100% (n=105)

Integrase Strand Transfer Inhibitors	
bictegravir (BIC)	Susceptible
cabotegravir (CAB)	Susceptible
dolutegravir (DTG)	Susceptible
elvitegravir (EVG)	Susceptible
raltegravir (RAL)	Susceptible

Mutation scoring: IN

HIVDB 9.5.1 (2023-11-05)

No drug resistance mutations were found for INSTI.